Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor

YANG Jiao; CHEN Junjun; ZHANG Xiangqi; ZHANG Jingxian; HAN Yonglong

doi:10.3969/j.issn.1006-0111.2017.06.009

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To investigate the inhibitory effect of Xiaoaiping injection (XAP) combined with paclitaxel (PTX) on human ovarian cancer SK-OV-3 cells. Methods In vitro anti-proliferation activity study of XAP combined with PTX on human ovarian cancer SK-OV-3 cells was performed using optical microscope and MTT assay. Human ovarian cancer SK-OV-3 cells were treated with PTX,XAP,PTX combined XAP or vehicle control.Each group of cells was treated with drugs for 24 h or 48 h.SK-OV-3 cell morphology was observed with optical microscope. MTT assay was used to detect the A value and cell viability was calculated. In vivo effect of XAP combined with PTX on the growth of SK-OV-3 cells was determined in nude mice. In our study, thirty-six mice were randomly divided into six groups:G1 (NS), G2 (PTX, 10 mg/kg), G3 (XAP, 20 ml/kg), G4 (XAP, 50 ml/kg), G5 (PTX 10 mg/kg+XAP 20 ml/kg) and G6 (PTX 10 mg/kg+XAP 50 ml/kg). Animals were treated for 18 days. Body weight, tumor volume and tumor inhibition rate were recorded and calculated. The results were analyzed by the SPSS 19.0 software. Results In vitro study showed that SK-OV-3 cell viability decreased significantly in PTX combined XAP group compared to PTX group or XAP group, in a time and dose-dependent manner. In vivo study showed that the combination of PTX and XAP resulted in decreased tumor weight significantly compared to the control or the PTX alone. Conclusion The combination of XAP and paclitaxel exhibited a synergistic effect both in vitro and in vivo in nude mouse tumor xenograft model.

Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor

Sixth People's Hospital East Branch Affiliated to Shanghai College of Medicine & Health Sciences, 201306 Shanghai, China

Received Date: 2017-01-04

Rev Recd Date: 2017-05-19

Key words:

Abstract: Objective To investigate the inhibitory effect of Xiaoaiping injection (XAP) combined with paclitaxel (PTX) on human ovarian cancer SK-OV-3 cells. Methods In vitro anti-proliferation activity study of XAP combined with PTX on human ovarian cancer SK-OV-3 cells was performed using optical microscope and MTT assay. Human ovarian cancer SK-OV-3 cells were treated with PTX,XAP,PTX combined XAP or vehicle control.Each group of cells was treated with drugs for 24 h or 48 h.SK-OV-3 cell morphology was observed with optical microscope. MTT assay was used to detect the A value and cell viability was calculated. In vivo effect of XAP combined with PTX on the growth of SK-OV-3 cells was determined in nude mice. In our study, thirty-six mice were randomly divided into six groups:G1 (NS), G2 (PTX, 10 mg/kg), G3 (XAP, 20 ml/kg), G4 (XAP, 50 ml/kg), G5 (PTX 10 mg/kg+XAP 20 ml/kg) and G6 (PTX 10 mg/kg+XAP 50 ml/kg). Animals were treated for 18 days. Body weight, tumor volume and tumor inhibition rate were recorded and calculated. The results were analyzed by the SPSS 19.0 software. Results In vitro study showed that SK-OV-3 cell viability decreased significantly in PTX combined XAP group compared to PTX group or XAP group, in a time and dose-dependent manner. In vivo study showed that the combination of PTX and XAP resulted in decreased tumor weight significantly compared to the control or the PTX alone. Conclusion The combination of XAP and paclitaxel exhibited a synergistic effect both in vitro and in vivo in nude mouse tumor xenograft model.

HTML

Reference (11)

[1]	Cowden Dahl K, Bobbs A, Cole J, et al. Emerging and evolving ovarian cancer animal models[J]. Cancer Growth Metast, 2015, 8(Suppl 1):29-36.
[2]	Shireen R, Brennan D, Flannelly G, et al. Survival in women with ovarian cancer before and after the introduction of adjuvant paclitaxel; a 25-year, single institution review[J]. Ir Med J, 2012, 105(2):47-50.
[3]	王淳, 李士怡, 王晓波, 等.消癌平注射液抑制卵巢癌细胞(Caov-3)侵袭的作用及可能机制[J].解剖科学进展, 2011, 17(2):144-146.
[4]	李凤霞, 宋爱英, 唐寅, 等.消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌的临床观察[J].中国药房, 2015, 26(20):2815-2817.
[5]	Harris JW, Rahman A, Kim BR, et al. Metabolism of taxol by human hepatic microsomes and liver slices:participation of cytochrome P4503A4 and an unknown P450 enzyme[J]. Cancer Res, 1994, 54(15):4026-4035.
[6]	Backman JT, Filppula AM, Niemi M, et al.Role of Cytochrome P4502C8 in drug metabolism and interactions[J]. Pharmacol Rev, 2016, 68(1):168-241.
[7]	Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine[J]. Proc Natl Acad Sci USA, 1997, 94(5):2031-2035.
[8]	Crommentuyn KM, Schellens JH, van den Berg JD, et al. In-vitro metabolism of anti-cancer drugs, methods and applications:paclitaxel, docetaxel, tamoxifen and ifosfamide[J]. Cancer Treat Rev, 1998, 24(5):345-366.
[9]	刘丽雅, 韩永龙, 余奇, 等. 消癌平注射液等4种抗肿瘤中药注射剂对人肝微粒体中CYP450酶7种亚型的体外抑制作用研究[J]. 中国临床药理学与治疗学, 2014, 19(5):522-527.
[10]	谢丽艳. 消癌平注射液药物相互作用研究[D]. 南京:南京中医药大学, 2013.
[11]	曾庆花. 消癌平注射液的药代动力学及相互作用研究[D]. 上海:第二军医大学, 2013.

Message Board

Antitumor activity of Xiaoaiping injection combined with paclitaxel on ovarian cancer SK-OV-3 cells and nude mouse with ovarian cancer SK-OV-3 transplantation tumor

doi: 10.3969/j.issn.1006-0111.2017.06.009

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views